Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab and Atezolizumab in Resectable NSCLC
NCT04832854Phase 2Terminated
- Sponsor
- Roche
- Start
- Apr 2021
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 5
01
Overview
A Phase 2 trial of tiragolumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Apr 2021; status: terminated.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04832854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04832854.